Molbio Diagnostics, the Indian molecular diagnostics company known for its portable Truenat PCR testing platform widely deployed for tuberculosis and COVID-19 detection, has secured Rs 281.5 crore from anchor investors ahead of its upcoming initial public offering (IPO).

The company aims to raise between Rs 904 crore and Rs 940 crore through the public issue. Proceeds are earmarked for infrastructure improvements and new equipment for its manufacturing facilities. Additionally, existing shareholders will sell portions of their holdings as part of the offering.

Anchor investor participation typically occurs a day before the IPO subscription opens, providing early momentum and price discovery. The strong anchor book comes as India's diagnostics sector continues to attract investor interest, driven by increasing demand for decentralised and point-of-care testing solutions across tier-2 and tier-3 markets. Molbio's Truenat platform, developed in partnership with the global health organisation FIND and others, has been adopted across numerous countries for rapid infectious disease detection, positioning the company at the intersection of diagnostics and public health infrastructure.

Molbio Diagnostics' shares are scheduled to debut on stock exchanges on August 17. Market participants will be watching subscription levels across retail and institutional segments, as well as the company's ability to expand its product pipeline beyond infectious disease testing into broader molecular diagnostics applications.

Source: Economic Times Markets